Peer-reviewed veterinary case report
Serum calcium-phosphorus levels predict survival in dogs with kidney
By Lippi, Ilaria et al.·Published in Journal of the American Veterinary Medical Association·2014·Department of Veterinary Science, Italy·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Prognostic role of the product of serum calcium and phosphorus concentrations in dogs with chronic kidney disease: 31 cases (2008-2010).
- Species:
- dog
Plain-English summary
A group of dogs with chronic kidney disease (CKD) were studied to see if their serum calcium and phosphorus levels could predict their chances of survival. The research found that dogs with a specific calcium-phosphorus product (sCaPP) greater than 70 mg²/dL² had a much higher risk of dying compared to those with lower levels. This means that if your dog has CKD and their sCaPP is high, it could indicate a more serious condition and a lower chance of recovery. It's important to monitor these levels with your veterinarian to manage your dog's health effectively.
People also search for: dog chronic kidney disease prognosis · high calcium phosphorus levels in dogs · CKD treatment for dogs
Abstract
OBJECTIVE: To investigate serum calcium-phosphorus concentration product (sCaPP) as a predictor of mortality rate in dogs with chronic kidney disease (CKD). DESIGN: Retrospective case-control study. ANIMALS: 31 dogs with definitive CKD and 35 apparently healthy dogs. PROCEDURES: All dogs had been referred for nephrological consultation between December 2008 and December 2010. Dogs with CKD had stable disease for ≥ 3 months. On the basis of glomerular filtration rate < 60 mL/min/m(2), 13 of the 35 apparently healthy dogs were subsequently classified as having early CKD. Disease stage among dogs was determined on the basis of plasma creatinine concentration as follows: stage 1, < 123.7 μmol/L (n = 13), stage 2, 123.7 to 176.8 μmol/L (7); stage 3, 185.6 to 442 μmol/L (13); or stage 4, > 442 μmol/L (11). For each dog, serum concentrations of ionized and total calcium and phosphorus were evaluated once; the latter 2 variables were used to determine sCaPP. RESULTS: The sCaPP differed significantly between the 22 healthy dogs and dogs with stage 3 or stage 4 CKD. The proportion of dogs with sCaPP > 70 mg(2)/dL(2) increased with stage of disease. Mortality rate among the 24 dogs with sCaPP > 70 mg(2)/dL(2) was higher than that among the 42 dogs with sCaPP ≤ 70 mg(2)/dL(2). Dogs with sCaPP > 70 mg(2)/dL(2) had a comparatively lower survival rate, and risk of death was 4.2 times as high as risk for dogs with sCaPP ≤ 70 mg(2)/dL(2). CONCLUSIONS AND CLINICAL RELEVANCE: For dogs with CKD, sCaPP > 70 mg(2)/dL(2) appeared to be a negative prognostic indicator, which was not influenced by the concomitant serum concentrations of phosphorus and total or ionized calcium.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/25356714/